VEGFR2/CD309 Antikörper (AA 20-762) (Biotin)
Kurzübersicht für VEGFR2/CD309 Antikörper (AA 20-762) (Biotin) (ABIN6757558)
Target
Alle VEGFR2/CD309 (VEGFR2) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 20-762
-
Spezifität
- Reacts specifically with human FLK-1/VEGFR-2/KDR. No cross-reactivity with VGFR-1/FLT-1 or FLT-4.
-
Aufreinigung
- Purified
-
Immunogen
- Recombinant human Flk-1.
-
Isotyp
- IgG
-
-
anti-VEGF Receptor 2 (VEGFR2) (AA 1326-1356), (C-Term) antibody
VEGFR2 Reaktivität: Human WB, FACS, IF, IHC (p) Wirt: Kaninchen Polyclonal RB01536 unconjugated
anti-VEGF Receptor 2 (VEGFR2) (pTyr951) antibodyVEGFR2 Reaktivität: Human, Maus, Ratte WB, IHC, ELISA, IF, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 20-242) antibodyVEGFR2 Reaktivität: Human WB, IHC, FACS, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 1326-1356) antibodyVEGFR2 Reaktivität: Human WB, IHC, ELISA, FACS, IF Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 101-200) antibodyVEGFR2 Reaktivität: Human, Maus, Ratte, Kaninchen ELISA, FACS, IHC (p), IF (p), IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 20-764) antibodyVEGFR2 Reaktivität: Human ELISA, FACS, ICC Wirt: Maus Monoclonal 4B4 unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 1225-1356) antibodyVEGFR2 Reaktivität: Human ELISA, FACS Wirt: Maus Monoclonal 1A9A3 unconjugated
anti-VEGF Receptor 2 (VEGFR2) (pTyr1214) antibodyVEGFR2 Reaktivität: Human, Maus, Ratte WB, IHC, ELISA, IF, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 454-469), (Middle Region) antibodyVEGFR2 Reaktivität: Human WB, IHC, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-VEGF Receptor 2 (VEGFR2) (AA 46-320) antibodyVEGFR2 Reaktivität: Ratte WB, IHC, IP, ICC Wirt: Kaninchen Polyclonal unconjugated
-
-
Applikationshinweise
-
Approved: ELISA (1:5000 - 1:50000)
Usage: Suitable for use in ELISA. ELISA: 1:10,000-1:100,000, using 50-100 ng of control peptide/well. The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested. -
Kommentare
-
Target Species of Antibody: Human
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Rekonstitution
- 100 μL sterile ddH20
-
Konzentration
- Lot specific
-
Buffer
- 100 mM Tris, pH 7.5, 0.2 % BSA, 0.05 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing cycles.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Can be stored at 4°C. For long term storage, aliquot and store at -20°C. Avoid freeze-thaw cycles.
-
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
Andere Bezeichnung
- KDR / VEGFR2
-
Hintergrund
-
Name/Gene ID: KDR
Subfamily: VEGF Receptor
Family: Protein Kinase
Synonyms: KDR, CD309, Fetal liver kinase 1, Fetal liver kinase-1, FLK-1, FLK1, Kinase insert domain receptor, Quek1, VEGFR, VEGFR2, Soluble VEGFR2, VEGF receptor 2, VEGFR-2, CD309 antigen, VEGF-R2 -
Gen-ID
- 3791
-
UniProt
- P35968
-
Pathways
- RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
Target
-
